DelveInsight has launched a new report on “CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL)- Market Insights, Epidemiology, and Market Forecast-2030
DelveInsight’s “CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL)– Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL), historical and forecasted epidemiology as well as the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
-
Market Size of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma in the 6MM is expected to be USD 2796.2 Million in 2030
-
Of the emerging therapies, the most anticipated products to get launched are JCAR017 (Celgene’s, (a BMS company) ), KTE-X19 (Gilead). Some of these products have also received Fastrack Designations and Orphan Designations.
Key benefits of the report:
1. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market report covers a descriptive overview and comprehensive insight of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) epidemiology and CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market report provides insights on the current and emerging therapies.
3. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4.The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market.
Request for sample pages: https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-non-hodgkins-lymphoma-market
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL): Overview
CAR T-cell therapy is a promising treatment for some patients with non-Hodgkin lymphoma (NHL) that has relapsed or has not responded to other therapies (refractory). It is a highly specialized therapy that involves genetically modifying a patient’s own T cells to attack their cancer.
The key players involved in CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market:
-
Gilead Sciences
-
Celgene Corporation (a BMS company)
The launch of the emerging therapies is expected to significantly impact the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL)treatment scenario in the upcoming years:-
Drug covered
-
KTE-X19
-
JCAR017
Request a free sample report @https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-non-hodgkins-lymphoma-market
Table of Contents
1.Report Introduction
2.Executive Summary
3.SWOT analysis
4.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Patient Share (%) Overview at a Glance
5.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Market Overview at a Glance
6.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Disease Background and Overview
7.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Epidemiology and Patient Population
8.Country-Specific Patient Population of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL)
9.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Current Treatment and Medical Practices
10.Unmet Needs
11.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Emerging Therapies
12.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Market Outlook
13.Country-Wise CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Market Analysis (2017–2030)
14.Market Access and Reimbursement of Therapies
15.Market drivers
16.Market barriers
17.Appendix
18.CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Report Methodology
19.DelveInsight Capabilities
20.Disclaimer
21.About DelveInsight
Related Reports:
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma- Pipeline Insight, 2021
“CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma – Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market. A detailed picture of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) pipeline landscape is provided, which includes the disease overview and CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/